Hyogo H, Ito K, Kido S, Yamamoto K, Kida M, Matsuda M, Kojima K, Matsuura M, Nakajima N, Akiyama J
Dept. of Gastroenterology, Shizuoka General Hospital.
Gan To Kagaku Ryoho. 1995 Sep;22(11):1577-81.
Six patients with advanced liver metastases judged as a survival limiting factor from lung cancer were treated with intra-arterial infusion chemotherapy employing totally implantable vascular access. The treatment regimen included 5-FU/CDDP/EPIR/MMC/etoposide in various combinations and this therapy was repeated as long as possible. There were no serious side-effects or complications, such as bone marrow suppression or gastrointestinal symptoms. The therapy could be continued for a mean duration of 7.2 months (ranging from 2 to 13 months). Cause of death was due to extra-hepatic lesion in all 5 patients. The direct effect on liver metastases reviewed on CT scan was 83.3% (CR: 1, PR: 4, NC: 1), and the median survival period was 108 days (for small-cell group: 92 days; for non-small-cell group: 407 days). We conclude that this therapy is useful in the treatment of liver metastases from lung cancer because of its limited toxicity and high direct effect.
六例因肺癌肝转移被判定为生存限制因素的晚期患者，采用完全植入式血管通路进行动脉内灌注化疗。治疗方案包括5-氟尿嘧啶/顺铂/表柔比星/丝裂霉素/依托泊苷的各种组合，只要可能就重复该治疗。没有出现严重的副作用或并发症，如骨髓抑制或胃肠道症状。该治疗的平均持续时间为7.2个月（范围为2至13个月）。所有5例患者的死亡原因均为肝外病变。CT扫描显示对肝转移的直接疗效为83.3%（完全缓解：1例；部分缓解：4例；疾病稳定：1例），中位生存期为108天（小细胞组：92天；非小细胞组：407天）。我们得出结论，该疗法因其毒性有限和直接疗效高，在治疗肺癌肝转移方面是有用的。
